ClinicalTrials.gg
Active, not recruitingNCT05027919Updated Nov 12, 2026

Assessing a Clinically-meaningful Opioid Withdrawal Phenotype

A Phase 2 interventional study of Hydromorphone and Naloxone + lofexidine pretreatment in Opioid Withdrawal, Opioid Use Disorder and Opioid Craving, sponsored by University of Maryland, Baltimore. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University of Maryland, Baltimore · Phase 2, Interventional, and Basic science

How we know

Updated Nov 12, 2026Now Active, not recruitingPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies testing lofexidine in Opioid-Related Disorders — none open to participants now, 1 under way, none of them phase 3. lofexidine · Opioid-Related Disorders.

Planned enrollment
7th of 15
60 · median 30
Started
2021
with 1 other
Phase 2
5 of 15
none open now
Registered
14th of 15
by date
Lead sponsor
1 of 15
University of Maryland, Baltimore

Among the 15 studies testing lofexidine in Opioid-Related Disorders, this one is the 7th largest by planned enrollment, is one of 2 that started in 2021, is one of 5 in phase 2, and was the 14th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

None of the 15 studies testing lofexidine in Opioid-Related Disorders is open now. The open studies under Opioid-Related Disorders, anywhere →

Where they have run

About lofexidine

lofexidine: first FDA approval 2018 (LUCEMYRA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing lofexidine in Opioid-Related Disorders as a file.
02

Study summary

Evaluate individual differences in the expression of opioid withdrawal symptoms in persons with opioid use disorder (OUD) while completing a clinically-indicated medication taper.

Read the detailed description

Individuals who have opioid use disorder and are interested in being tapered off of opioids will be admitted to a residential research unit for an 11-day period. All participants will be maintained on morphine for 5 days. During this period participants will complete 2 sessions (on two different days) wherein participants will receive an intramuscular injection of naloxone to precipitate a short withdrawal syndrome. Participants will take a capsule prior to both sessions that will contain either placebo or the opioid withdrawal medication lofexidine. Beginning on day 6 participants will be tapered off of morphine using lofexidine (as clinically indicated). At the end of the study all participants will be able to transition to buprenorphine maintenance or receive oral naltrexone and an injection of Vivitrol (extended release naltrexone), consistent with standard of care practices. Investigators will collect a variety of biological samples and questionnaire ratings during the study and primary outcomes will be measures of withdrawal collected throughout the study. Investigators will use these data to learn more about why individuals express opioid withdrawal symptoms differently, which will help inform how to change current treatment practices to be more effective for persons with OUD.

03

Conditions studied

  • Opioid Withdrawal
  • Opioid Use Disorder
  • Opioid Craving
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years - 65 year old
  • Opioid-positive urine sample
  • Current opioid use disorder with evidence of physical dependence
  • Interest in undergoing opioid taper

Exclusion criteria

Exclusion Criteria:

  • Evidence of physical dependence on alcohol or benzodiazepines that requires medical intervention
  • Being pregnant or breastfeeding
  • Enrolled in methadone or buprenorphine maintenance treatment
  • hypotension (\<90/60mmHg) or bradycardia (\<45bpm)
  • History of myocardial infarction
  • Subjects who are positive for surface antigen and/or antibody with liver function tests outside the normal range (persons with a positive hepatitis C antibody and normal liver functions tests are NOT excluded from the study)
  • Significant mental health or physical disorder, or life circumstances, that is expected to interfere with study participation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Other
    Within-subject design

    All participants will undergo the same study design, which includes hydromorphone stabilization (days 1-5), two naloxone challenges (scheduled during morphine stabilization), lofexidine-assisted taper (days 6-10), and transition to aftercare (day 11).

    Drug: Hydromorphone · Drug: Naloxone + lofexidine pretreatment · Drug: Naloxone + placebo pretreatment · Drug: Lofexidine

Interventions

  • Up to 120mg oral per day in q4 dosing to manage withdrawal

  • DrugNaloxone + lofexidine pretreatment

    0.2-0.4mg naloxone injection during the Naloxone challenge + pretreatment with oral lofexidine (25% of max daily dose scheduled during lofexidine taper)

  • DrugNaloxone + placebo pretreatment

    0.2-0.4mg naloxone injection during the Naloxone challenge

  • Oral Lofexidine dosed per FDA label (4 times daily) on days 6 through 10.

06

What researchers measure

Primary outcomes

  1. Withdrawal severity during lofexidine taper

    Withdrawal severity as assessed by the Subjective Opioid Withdrawal Scale. (The score range is 0 through 64) with higher score indicating more severe withdrawal.

    Time frame: Days 6 through 10

  2. Withdrawal severity during naloxone challenge

    Withdrawal severity as assessed by the Subjective Opioid Withdrawal scale scores (The range is 0 through 64) with higher score indicating more severe withdrawal. Collected during two naloxone challenges (pretreatment with lofexidine and pretreatment with placebo).

    Time frame: Days 1 through 5

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Jan 2027, 61 months after the start.

Of 61 non-industry phase 2 interventional studies under Opioid-Related Disorders, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 55. This study's planned 61 months is above that.

Counting every sponsor, half of 68 studies reached it within 40 months; a quarter within 23 and three quarters within 55.

Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2026 → Jan 2027, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2021
First posted
Aug 31, 2021
StartActual
Dec 1, 2021
Primary completionEst.
Jan 30, 2027was Nov 2026
CompletionEst.
Feb 28, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 12, 2026
Primary completion
Nov 30, 2026→Jan 30, 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Active, not recruiting
    Primary completion Nov 30, 2026→Jan 30, 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05027919
Responsible party
Sponsor
First posted
Aug 31, 2021
Start date
Dec 1, 2021
Primary completion
Jan 30, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Kelly E Dunn, Ph.D, M.B.A.
principal investigator · University of Maryland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Hydromorphone · Lofexidine

Start the discussion